These data suggested that the STAT5 inhibitor pimozide attenuated the ability of cells to pump out drugs and sensitized DOX-resistant breast cancer cells to DOX by suppressing the STAT5a/ABCB1 pathway. Here, STAT5A is linked to breast carcinoma.